Anti-allergic effects of His-Ala-Gln tripeptide in vitro and in vivo.

Abstract	We examined the inhibitory effects of HAQ (His-Ala-Gln) peptide on type-1 allergy in vitro and in vivo. HAQ peptide inhibited β-hexosaminidase release and intracellular Ca2+ levels of rat basophilic leukemia RBL-2H3 cells. Oral administration of a HAQ peptide-added diet (1 mg/mouse/administration) to C3H/HeJ mice for 14 days led to significant suppression of allergic symptoms, but did not reduce allergen-specific IgE or IgG1.
Authors	Mamoru Tanaka, Hiroyuki Watanabe, Yoshinobu Yoshimoto, Hana Kozai, Takeaki Okamoto
Journal	Bioscience, biotechnology, and biochemistry (Biosci Biotechnol Biochem) Vol. 81 Issue 2 Pg. 380-383 (Feb 2017) ISSN: 1347-6947 [Electronic] England
PMID	27728999 (Publication Type: Journal Article)
Chemical References	Anti-Allergic Agents Immunoglobulin G Oligopeptides histidyl-alanyl-glutamine Immunoglobulin E beta-N-Acetylhexosaminidases Calcium
Topics	Administration, Oral Animals Anti-Allergic Agents (administration & dosage, pharmacology, therapeutic use) Calcium (metabolism) Cell Line, Tumor Hypersensitivity (blood, drug therapy) Immunoglobulin E (blood) Immunoglobulin G (blood) Intracellular Space (drug effects, metabolism) Mice Oligopeptides (administration & dosage, pharmacology, therapeutic use) Rats beta-N-Acetylhexosaminidases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!